You are here

Pharmaceuticals and Healthcare

The business of vital innovation

Share

The pharmaceutical and healthcare sector is one of the world’s most vital and innovative.

Against a backdrop of technological change and an increasing and aging population, we partner with our clients to help them achieve their goals, capitalise on opportunities and navigate uncertainty.

Combining deep scientific, technical and strategic knowledge we help our clients by providing the commercial nous, experience and range of services that only a large international professional services firm can offer, to anticipate and deliver innovative and value-enhancing solutions.

Recent Experience

Indivior plc

in connection with the Relationship Agreement and settlement reached with the Company’s largest shareholder, the activist investor Scopia Management

Parkinson's UK

on its acquisition of assets relating to the research, development, manufacture and marketing of glial-cell line-derived neurotrophic factor (GDNF), a potentially disease-modifying treatment for Parkinson's disease

SK Holdings

on its acquisition of Yposkesi, a French market leader in gene therapy and viral vector manufacturing

Acacia Research Corporation

on its entry into an agreement with Link Fund Solutions Limited to purchase shares in up to 19 public and private life sciences companies from the LF Equity Income Fund for up to £223.9 million.

FederFARMACO

a company representing pharmaceutical wholesalers, on regulatory affairs and intellectual property matters

Mirnagreen

 in relation to the launch and correct classification of new products based on a disruptive technology for extracting microRNA from plants, including advising on strategy to mitigate risks related to a misclassification under the contiguous categories of medicinal products, novel food and food supplements

Diverse knowledge and in-depth expertise

Related news and deals

13 July 2021

Herbert Smith Freehills advises sponsors on Brii Biosciences’ HK$2.483 billion Hong Kong IPO 史密夫斐尔律师事务所作为联席保荐人境外律师为腾盛博药24.83亿港元IPO提供法律服务

07 April 2021

Nanda Lau to lead Herbert Smith Freehills’ China corporate practice 刘依兰将领导史密夫斐尔中国公司事务

22 March 2021

2021 M&A predictions hold up in first quarter, but challenges remain